Condition

HIV/AIDS - Drug-susceptible Tuberculosis

Clinical trials and treatment information for HIV/AIDS - Drug-susceptible Tuberculosis

1.7M
People Affected
150
Active Trials
300K
New Cases/Year
183K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen
90% Effectiveness• 95% Confidence• 60% Safety• 5000 trials• 5M participants
HIGH EvidenceExcellent ValueDose: Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion

Duration

6 months (2 months intensive, 4 months continuation)

Response Rate

90%

Remission Rate

85%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

20

Common Side Effects:

Hepatotoxicity (elevated LFTs, hepatitis): 8%
Peripheral neuropathy: 5%
Gastrointestinal upset (nausea, vomiting, abdominal pain): 15%
Orange/red discoloration of urine/tears/sweat: 99%
Arthralgia: 15%
Optic neuritis: 3%
Rash: 3%

Annual Cost of Care

Drug Cost

$680

Monitoring

$2,300

Side Effects

$350

Total Annual

$3,330

Cost-Effectiveness

EXCELLENT

QALYs Gained

12

ICER

$8,000/QALY

Cost per Remission

$3,918

Cost per Responder

$3,700

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Hepatotoxicity (elevated LFTs, hepatitis)
+8%
Peripheral neuropathy
+5%
Gastrointestinal upset (nausea, vomiting, abdominal pain)
+15%

Clinical Trial Phases:

Phase 4
2
4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen
88% Effectiveness• 85% Confidence• 55% Safety• 50 trials• 20K participants
HIGH EvidenceExcellent ValueDose: Weight-based daily dosing for Rifapentine, Moxifloxacin, Isoniazid, Pyrazinamide
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe

Time to Effect

1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion

Duration

4 months

Response Rate

88%

Remission Rate

83%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

25

Common Side Effects:

Gastrointestinal upset (nausea, vomiting, diarrhea): 20%
Hepatotoxicity (elevated LFTs, hepatitis): 8%
Peripheral neuropathy: 5%
Orange/red discoloration of urine/tears/sweat: 99%
Rash: 7%
QT prolongation: 1%

Annual Cost of Care

Drug Cost

$1,160

Monitoring

$1,500

Side Effects

$400

Total Annual

$3,060

Cost-Effectiveness

EXCELLENT

QALYs Gained

12

ICER

$7,500/QALY

Cost per Remission

$3,687

Cost per Responder

$3,477

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+83%
Common Side Effects
Gastrointestinal upset (nausea, vomiting, diarrhea)
+20%
Hepatotoxicity (elevated LFTs, hepatitis)
+8%
Peripheral neuropathy
+5%

Clinical Trial Phases:

Phase 3Phase 4